Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine for Pessary Removal Pain
NCT05493735Phase 3Completed
- Sponsor
- University of South Florida
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of lidocaine 10% oropharyngeal spray in pelvic organ prolapse (POP) and stress urinary incontinence (SUI) (2 arms), sponsored by University of South Florida. Primary endpoint: Change in patient's pain using the visual analog scale (VAS) after pessary removal. Started Sep 2022; status: completed.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
pelvic organ prolapse (POP)stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT05493735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493735.